▎ WuXi AppTec content team reports

Recently, Di zhe Pharmaceutical announced that the first registered study of suvotinib in patients with advanced non-small cell lung cancer (NSCLC) who had previously received platinum chemotherapy and carried EGFR exon20ins had reached the main endpoint

NSCLC accounts for about 85% of lung cancers, and EGFR mutations are a common type of genetic mutation in

Suvotinib is an oral, irreversible, highly selective EGFR tyrosine kinase inhibitor (TKI) for multiple subtypes of EGFR mutations whose preferred indication is for the treatment of EGFR exon20ins mutant NSCLC

The WU-KONG6 study, presented at ESMO, was an open, single-arm, multi-center Phase 2 registration trial conducted in China with the primary endpoint being orR confirmed by the Blind Independent Center Evaluation Committee (BICR), and the results showed:

• As of July 31, 2022, 97 patients with advanced NSCLC who had failed chemotherapy treatment with suvotinib (300 mg QD) were included in the efficacy analysis set, and the clinical study was judged by BICR to reach a preset primary endpoint, with a confirmed ORR of up to 59.

  
  

• 31 patients with baseline with brain metastases accounted for 32%, and the confirmed ORR was as high as 48.

  
  
• A total of 30 subtypes of EGFR exon20ins mutations were included, and antitumor activity
  
  

  ▲If you have any business needs, please long press to scan the QR code above, or